Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Pfizer buys into inflammation and immunology; bispecifics and CAR-Ts in the spotlight at ASH; Lilly looks to volume-driven growth; and Novavax talks about diversity in clinical trials.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 17 December 2021, including: Pfizer Inc. buys into inflammation and immunology; bispecifics and CAR-Ts in the spotlight at ASH; Eli Lilly and Company looks to volume-driven growth; and Novavax, Inc. talks about how diversity in clinical trials.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Pfizer Buys Arena For $6.7bn In Bid To Diversify In Inflammation & Immunology" - Scrip, 13 Dec, 2021.)
(Also see "Yescarta, Breyanzi Offer Practice-Changing Options For Second-Line LBCL" - Scrip, 12 Dec, 2021.)
(Also see "Lilly Looks To Volume-Driven Growth In Decade Ahead" - Scrip, 15 Dec, 2021.)
(Also see "For Novavax, Building Trust Was Key To Improving Diversity" - Scrip, 14 Dec, 2021.)